Start here: deposits where they should not be
Amyloid is a general term for proteins that have misfolded and clumped into abnormal, insoluble aggregates. Such deposits turning up inside muscle tissue is notable, because they do not belong there and could interfere with how the muscle works, including its blood supply and energy metabolism.
In long COVID, the report of amyloid-containing deposits in muscle is one of the more striking observations, and it raises the possibility that the fatigue has a structural element on top of the metabolic ones described elsewhere.
The link it proposes
The significance of these deposits is partly in what they may connect to. The same broad amyloid family appears in the fibrinaloid microclot hypothesis, where abnormal fibrin forms amyloid-like clots.1 Muscle amyloid deposits could therefore link the fatigue mechanism to the microclot and vascular pathway.
If that connection held, it would tie two of long COVID's major threads together: the muscle-level energy problem and the vascular clotting hypothesis, suggesting a shared process of abnormal protein aggregation.
low-moderatecontestedlinks to microclot pathway
Why to hold it loosely
The honest grading is low-to-moderate and contested. The deposits are a real observation, but their cause, their prevalence, and their actual contribution to symptoms are unsettled, and the link to the microclot pathway shares the caution that attaches to that hypothesis.
This is a thread to follow with interest rather than a mechanism to rely on. It is the kind of finding that could become important or could turn out to be a marker of something else, and the evidence is not yet there to tell.
How it might cause harm
If the deposits are relevant, there are plausible routes by which they could contribute to fatigue: interfering with muscle energy metabolism, disrupting the local blood supply, or provoking low-grade inflammation in the tissue. Each would compound the metabolic problems seen in the same muscle.
These are reasonable hypotheses rather than demonstrated mechanisms. The deposits could be a cause, a consequence, or an incidental marker, and distinguishing those possibilities is exactly what the evidence has not yet done.
Where it sits among the muscle findings
Alongside reduced oxidative phosphorylation and the glycolytic shift, the amyloid deposits add a third, more speculative dimension to the muscle picture. The first two are well-founded; this one is contested, so it should be weighted accordingly rather than treated as their equal.
Its appeal is integrative: it gestures at a connection between the fatigue and vascular stories. But an attractive connection is not a proven one, and the responsible reading keeps the well-founded findings central and this one provisional.
What it means for you
For now, this finding changes nothing practical. There is no test for these deposits in ordinary care and no treatment aimed at them, and the link to microclots does not justify the unproven, sometimes risky anticoagulation protocols promoted on the strength of the microclot hypothesis.
Its value is as a piece of the research picture, a hint that the fatigue and vascular mechanisms might share a thread. Worth knowing, worth watching, and not yet worth acting on.
What we don't know
Honest about the edges of the evidence. These are open questions, not settled answers.
- Whether the amyloid deposits genuinely contribute to fatigue or are incidental.
- How common they are in long COVID muscle.
- Whether they truly connect to the microclot pathway or merely resemble it.
- What causes the deposits to form in muscle.
- Whether they are a cause, a consequence, or a marker.
- Whether they have any treatment implication.
What this means for you
If you have read that abnormal protein deposits in muscle might tie long COVID fatigue to the microclot story, the deposits are a real observation, but the connection is contested and unsettled. It is an intriguing thread, not an established mechanism, and it deserves interest rather than confidence.
Practically, it changes nothing yet: there is no test for it in ordinary care, no treatment aimed at it, and it does not justify the unproven anticoagulation protocols promoted around microclots. Keep the well-founded muscle findings, the energy and fibre changes, central, and hold this one as a hint worth watching rather than a basis for action.
Treat this as a thread to watch, not a basis to act. The deposits are real and the possible link to the microclot pathway is intriguing, but both are unsettled, and neither justifies the unproven anticoagulation protocols promoted around microclots. Keep the well-founded muscle findings central, hold this provisional one lightly, and let the research mature before reading anything practical into it. The honest stance is curiosity without commitment: note the possible bridge between fatigue and the vascular story, and wait for evidence that can actually bear weight before letting an intriguing observation change anything you actually do day to day. For now it explains nothing you can act on, and that is the honest place to leave it.
References
Each reference links to the source on PubMed, PMC, or the publisher.